In the same way, ATM and BRCA2 somatic mutations are suggested to be biomarkers that predict response to stage III CRC patients that received oxaliplatin-based chemotherapy, and they are associated with recurrence-free survival [63]. The gene discussed is BRCA2; the disease is colorectal carcinoma.